Envision Pharma Group – New Office in Wilmslow, Cheshire, Opening in March 2016

PR icon


Jan 5, 2016

Envision Pharma Group – New Office in Wilmslow, Cheshire, Opening in March 2016

Horsham, UK, 5 January, 2016 – Envision Pharma Group (“Envision”), a highly successful Medical Affairs-focused, technology-enabled scientific communications company is expanding into the North West of England to complement its nine other offices in the UK, US, and Asia-Pacific. As part of its continued expansion, Envision is delighted to announce the opening of its newest office in Wilmslow, Cheshire, in March 2016. As well as serving as a North West office for the expansion of Envision’s core services, Wilmslow will also act as a head office for the Alligent Group’s (“Alligent”) European operations. Alligent, a leading Medical Affairs agency that develops and delivers strategically-focused, integrated and aligned medical communications solutions to the biopharma industry, became part of the Envision Pharma Group in September, 2015. 


The Envision Pharma Group, including the Alligent European team, will be recruiting for Scientific Directors, Medical Writers, Account Managers and Account Directors from January, 2016.

For an informal discussion, or to apply for any of the roles, please contact Karen Kent (Envision Pharma Group Recruiter – Karen.Kent@EnvisionPharmaGroup.com) or David Thompson (MD at Alligent − David.Thompson@AlligentGroup.com).


Alligent’s core skill sets of medical strategy development and planning, allied program implementation, and stakeholder support are now integrated with Envision’s existing services of strategic data dissemination – including publication planning, consultancy, and market access communications – to provide global Medical Affairs Departments with compliant, strategically-focused evidence-based communication programs. Underpinning its services, the expanded Envision Pharma Group will continue to provide its expansive client base with industry-leading technology including Datavision®, Visiontracker®, Clear™ and Medinfo™.


Envision’s CEO, Brian Hepburn, commented, “The addition of Alligent to the Envision Pharma Group further cemented our core tenet of becoming the leading international medical affairs agency and expanded the capabilities we offer to medical affairs teams to ensure optimal, evidence communication. The new office in Wilmslow, not only provides a base for Alligent’s European operations, but continues Envision’s structured expansion with an office in the North West of England, a traditional centre of excellence for the medical communications industry.”


Alligent Group partners, David Thompson and Joe Kohles, added, “We are tremendously excited to begin a new era for Alligent Group with the establishment of a European headquarters allowing us to more effectively serve our European clients, as well as attract some of the best talent in the medical communications industry.”  


About Envision

Founded in 2001, Envision Pharma Group is an international, innovative, global technology and scientific communication company serving the medical affairs requirements of pharmaceutical, biotechnology, and medical device companies. Initially focusing on publication planning, Envision has evolved to become a leading provider of evidence-based communication services, encompassing all aspects of scientifically driven data dissemination activities required to support a successful “access to market strategy” for new biopharma products.


This capability of the organization is further enhanced with industry-leading, complementary technology solutions. Envision has grown steadily under consistent leadership across its three core business areas in support of the Medical Affairs Team that include (i) Evidence Communication – including strategic publication planning, data dissemination services, Med Ed and market access communications; (ii) Technology Solutions – design, development, implementation, and support of innovative and strategic management software for life-science clients including publication planning and management (Datavision®), clearance approval (ClearTM), and activity request management (Visiontracker®); and (iii) Consulting Solutions – policy, process, compliance, and guideline consultancy to life-science companies.


Envision currently has nine offices, two in the United Kingdom – Horsham and London, five in the United States including offices in Philadelphia, PA, Southport, CT, Madison, NJ, Stirling, NJ,  Glastonbury, CT, and two in Asia-Pacific – Tokyo and Sydney. The company employs approximately 410 team members, including over 160 highly qualified and experienced in-house medical writers and a 65-strong technology solutions team providing platform development and customer support. Envision currently provides service and product solutions to more than 75 client companies, including 19 of the top 20 pharmaceutical companies.


About the Alligent Group

Alligent was acquired by the Envision Pharma Group in September, 2015. Alligent was built to support the strategic and tactical needs of our clients’ medical directors and currently provides strategic medical planning and program implementation for the Medical Affairs Departments of a number of leading biopharma organizations. Based in Stirling, NJ, the company employs over 30 communications and scientific experts with extensive industry and agency experience, particularly within the area of oncology. 


Envision Pharma Group logo